ROR1 BiTE

ROR1 BiTE (Receptor Tyrosine Kinase-Like Orphan Receptor 1 Bispecific T-cell Engager) is a bispecific antibody construct designed to redirect the cytotoxic activity of T cells against tumor cells expressing ROR1. The molecule typically utilizes the BiTE architecture, consisting of two linked single-chain variable fragments (scFvs) that simultaneously target the CD3 epsilon subunit on T cells and ROR1 on malignant cells. ROR1 is a type I orphan receptor that is highly expressed in various hematological malignancies (such as chronic lymphocytic leukemia and mantle cell lymphoma) and solid tumors (including breast, pancreatic, and lung cancers), while being largely absent in healthy adult tissues. By cross-linking these targets, the BiTE facilitates the formation of an immunological synapse, leading to T-cell activation and the subsequent lysis of ROR1-expressing cancer cells. While originally characterized in academic research settings, such as the Scripps Research Institute, the ROR1-targeting T-cell engager platform has informed the development of several clinical-stage candidates, including Nuvigene's NVG-111 and related formats like EpimAb Biotherapeutics' MAT-Fab construct EMB-07.

Other names

ROR1 x CD3 bispecific T-cell engagerROR-1 x CD3 bispecific T-cell engagerROR 1 x CD3 bispecific T-cell engager